Milestone Pharmaceuticals’ (MIST) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of Milestone Pharmaceuticals (NASDAQ:MIST) in a report issued on Friday morning,Benzinga reports. HC Wainwright currently has a $25.00 target price on the stock.

Milestone Pharmaceuticals Stock Performance

MIST stock opened at $1.63 on Friday. The company has a market cap of $86.92 million, a P/E ratio of -2.01 and a beta of 1.80. Milestone Pharmaceuticals has a 1 year low of $1.12 and a 1 year high of $2.75. The company has a debt-to-equity ratio of 2.18, a current ratio of 15.40 and a quick ratio of 15.40. The stock’s fifty day moving average price is $2.06 and its 200-day moving average price is $1.76.

Hedge Funds Weigh In On Milestone Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the company. Jones Financial Companies Lllp boosted its stake in shares of Milestone Pharmaceuticals by 1,000.0% in the 4th quarter. Jones Financial Companies Lllp now owns 11,000 shares of the company’s stock worth $26,000 after buying an additional 10,000 shares during the last quarter. National Bank of Canada FI raised its holdings in Milestone Pharmaceuticals by 163.4% in the 4th quarter. National Bank of Canada FI now owns 18,700 shares of the company’s stock worth $44,000 after purchasing an additional 11,600 shares during the period. PVG Asset Management Corp bought a new position in Milestone Pharmaceuticals in the 3rd quarter worth $46,000. Cubist Systematic Strategies LLC bought a new position in Milestone Pharmaceuticals in the 4th quarter worth $73,000. Finally, XTX Topco Ltd bought a new position in Milestone Pharmaceuticals in the 4th quarter worth $80,000. 86.18% of the stock is currently owned by hedge funds and other institutional investors.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.